p.s. The two FDA-approved FoBs are NVS’ Zarxio (#msg-111475426) and PFE/Celltrion’s Inflectra (#msg-121701314), which are FoBs’ for AMGN’s Neupogen and JNJ’s Remicade, respectively.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”